Buy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive Edge
Jason Zemansky, an analyst from Bank of America Securities, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The ...
Scientific American4d
Meeting Developmental Milestones Early Doesn’t Always Predict Success
Developmental milestones help us understand when a child needs help, but meeting them early doesn’t necessarily predict ...
Pharmaceutical Technology16d
SAR-442501 by Sanofi for Achondroplasia: Likelihood of Approval
SAR-442501 is under clinical development by Sanofi and currently in Phase I for Achondroplasia. According to GlobalData, Phase I drugs for Achondroplasia does not have sufficient historical data to ...
Pharmaceutical Technology16d
Infigratinib phosphate by QED Therapeutics for Achondroplasia: Likelihood of Approval
Infigratinib phosphate is under clinical development by QED Therapeutics and currently in Phase III for Achondroplasia. According to GlobalData, Phase III drugs for Achondroplasia does not have ...
Yahoo Finance1mon
Advancements and Opportunities in the Achondroplasia Market: A Comprehensive Analysis and Forecast to 2032
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Market Overview A ...
News Medical5y
Achondroplasia News and Research
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's ...